➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Colorcon
Moodys
Express Scripts
Mallinckrodt

Last Updated: November 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NEO-MEDROL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Neo-medrol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00023231 Pediatric Kidney Transplant Without Calcineurin Inhibitors Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 2001-02-01 The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease. However, it has been difficult to find treatment for donor graft rejection that does not have a lot of side effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects. One approach is to avoid using calcineurin inhibitors and to try a new drug known as sirolimus instead. Another is to use steroids less often. This study will test whether using sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term graft survival in children receiving kidney transplants from living donors.
NCT00104299 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed Genentech, Inc. Phase 2/Phase 3 2005-01-01 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed Immune Tolerance Network (ITN) Phase 2/Phase 3 2005-01-01 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2/Phase 3 2005-01-01 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00241982 Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis Completed Utrecht University Phase 2 2005-10-01 Trial to study the safety of a single, intravenous administration of long-circulating liposomal prednisolone disodium phosphate in patients with active rheumatoid arthritis.
NCT00241982 Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis Completed Radboud University Phase 2 2005-10-01 Trial to study the safety of a single, intravenous administration of long-circulating liposomal prednisolone disodium phosphate in patients with active rheumatoid arthritis.
NCT00279903 Is Botox Effective in Relieving Pain From Knee Osteoarthritis? Completed Mayo Clinic Phase 1 2005-11-01 Patients with painful knee osteoarthritis will be randomly allocated to one of three groups. Each group will receive a knee injection of: 1) cortisone, 2) low dose Botox, or 3) high dose Botox. Patients will then be followed for 6 months to see if they have significant pain relief or improvement in their activity level after the injection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Neo-medrol

Condition Name

Condition Name for Neo-medrol
Intervention Trials
Osteoarthrosis 6
Leukemia 5
Rheumatoid Arthritis 3
Kidney Failure 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Neo-medrol
Intervention Trials
Osteoarthritis 11
Joint Diseases 6
Precursor Cell Lymphoblastic Leukemia-Lymphoma 5
Leukemia, Lymphoid 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Neo-medrol

Trials by Country

Trials by Country for Neo-medrol
Location Trials
United States 38
Denmark 9
India 3
Netherlands 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Neo-medrol
Location Trials
Texas 8
Indiana 4
New York 3
Maryland 3
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Neo-medrol

Clinical Trial Phase

Clinical Trial Phase for Neo-medrol
Clinical Trial Phase Trials
Phase 4 6
Phase 3 12
Phase 2/Phase 3 4
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Neo-medrol
Clinical Trial Phase Trials
Recruiting 16
Completed 14
Not yet recruiting 12
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Neo-medrol

Sponsor Name

Sponsor Name for Neo-medrol
Sponsor Trials
M.D. Anderson Cancer Center 7
Bispebjerg Hospital 7
Rigshospitalet, Denmark 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Neo-medrol
Sponsor Trials
Other 61
Industry 18
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Johnson and Johnson
Express Scripts
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.